Well, putting it bluntly, losing the chance for approval with Medsafe has put paid to the idea of a commercial phase 3 trial. The fate of the shareholders now rests on the company's ability to negotiate a favourable agreement with big pharma for a phase 3 trial...
There's no emoji here for my feelings on that.
Ann: Preliminary Final Report and 2019 Financial Statements, page-18
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $21.26K | 3.022M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 8514049 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1168300 | 11 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |